Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (CLLS) released its monthly disclosure under Article 223-16 of the French financial markets authority, detailing share capital and voting rights. As of July 31, 2026, the company reported 100,701,207 shares outstanding and a total of 105,554,794 voting rights.

The listing market is Euronext Growth, and the company’s ISIN code is FR0010425595. Cellectis also provided dedicated media and investor relations contacts for further information on this voting rights update.

Market Context

The active F-3 shelf, effective through Jul 02, 2028, places this monthly share-capital disclosure w...

Analysis

The active F-3 shelf, effective through Jul 02, 2028, places this monthly share-capital disclosure within a broader financing context. The platform also recorded no recent insider activity; subsequent filings would clarify whether shelf usage changes.

Key Figures

Reporting date: 07/31/2026 Shares in capital: 100,701,207 shares Voting rights: 105,554,794 voting rights

3 metrics

Reporting date 07/31/2026 Monthly share-capital disclosure

Shares in capital 100,701,207 shares As of July 31, 2026

Voting rights 105,554,794 voting rights As of July 31, 2026

Historical Context

5 past events · Latest: Jul 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 02	Monthly capital disclosure	Neutral	-0.3%	Monthly share-capital and voting-rights disclosure for June 30, 2026
Jun 25	Shareholder meeting results	Neutral	-2.1%	Shareholders adopted resolutions 1 through 29 and rejected resolution 30
Jun 11	Clinical data update	Positive	-2.8%	Final Phase 1 lasme-cel and preliminary eti-cel clinical results
Jun 09	FDA designation	Positive	+6.3%	FDA RMAT designation for lasme-cel in relapsed/refractory B-ALL
Jun 03	Monthly capital disclosure	Neutral	+1.9%	Monthly share-capital and voting-rights disclosure for May 31, 2026

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Reactions to comparable monthly disclosures were mixed (-0.3% and +1.94%), while clinical news diverged (-2.83%) and FDA news aligned (+6.35%).

Key Terms

article 223-16, isin code

2 terms

article 223-16 regulatory

"Article 223-16 of General Regulation of the French financial markets authority"

Article 223-16 is a rule that requires certain financial firms, like banks and investment companies, to report their large or suspicious transactions to authorities. This helps prevent illegal activities such as money laundering or fraud, making the financial system safer and more transparent.

isin code technical

"Listing market: Euronext Growth ISIN code: FR0010425595"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Aug. 05, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
07/31/2026	100,701,207	105,554,794

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• Voting_Rights_PR_July_2026_EN

FAQ

What are Cellectis (CLLS) total shares outstanding as of July 31, 2026?

Cellectis reported 100,701,207 shares outstanding as of July 31, 2026. According to Cellectis, this figure represents the total number of shares in its share capital, disclosed under Article 223-16 for the Euronext Growth listing.

How many voting rights does Cellectis (CLLS) have on July 31, 2026?

Cellectis reported 105,554,794 voting rights as of July 31, 2026. According to Cellectis, this monthly publication provides investors with the current total of exercisable voting rights linked to the company’s outstanding share capital on Euronext Growth.

Why did Cellectis (CLLS) publish voting rights information in August 2026?

Cellectis published its voting rights and share capital information to comply with Article 223-16 disclosure rules. According to Cellectis, the August 5, 2026 update reflects figures effective on July 31, 2026 for its Euronext Growth listing.

What listing market and ISIN code does Cellectis (CLLS) use in the July 2026 voting rights update?

Cellectis identifies Euronext Growth as its listing market and uses ISIN code FR0010425595. According to Cellectis, these identifiers accompany the monthly disclosure of share capital and voting rights required by French market regulations.

How often does Cellectis (CLLS) disclose its total voting rights and share capital?

Cellectis provides a monthly update of its total shares and voting rights under Article 223-16. According to Cellectis, the July 31, 2026 figures were reported on August 5, 2026 as part of this recurring regulatory disclosure process.

Who are the investor relations contacts for Cellectis (CLLS) regarding the July 2026 voting rights data?

For investor questions, Cellectis lists Arthur Stril, Chief Financial Officer and Chief Business Officer, via investors@cellectis.com. According to Cellectis, separate media contacts, including Pascalyne Wilson and Patricia Sosa Navarro, are also available for inquiries about this voting rights update.